Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.

Jonas Hjelmgren; Ola Ghatnekar; Jan Reimer; Martin Grabowski; Olle Lindvall; Ulf Persson; Peter Hagell

doi:10.1016/j.parkreldis.2006.04.006

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.

Jonas Hjelmgren, Ola Ghatnekar, Jan Reimer, Martin Grabowski, Olle Lindvall, Ulf Persson, Peter Hagell

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

228 Nedladdningar (Pure)

Sammanfattning

A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved.

Originalspråk	engelska
Sidor (från-till)	443-452
Tidskrift	Parkinsonism & Related Disorders
Volym	12
Nummer	7
DOI	https://doi.org/10.1016/j.parkreldis.2006.04.006
Status	Published - 2006

Bibliografisk information

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Section I-II (013230011), Division IV (013230800), Division of Gerontology and Caring Sciences (Closed 2012) (013220200), Restorative Neurology (0131000160), Neurology, Lund (013027000), Caring Sciences (Closed 2012) (016514020)

Ämnesklassifikation (UKÄ)

Neurologi

Tillgång till dokument

10.1016/j.parkreldis.2006.04.006

HagellElsevier

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16798054&dopt=Abstract

Andra filer och länkar

Link to publication in Scopus

Citera det här

@article{f26aa2f543794568a9adb687457477ad,

title = "Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.",

abstract = "A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved.",

keywords = "cell, therapy, cost-effectiveness, Parkinson's disease, outcomes, modeling",

author = "Jonas Hjelmgren and Ola Ghatnekar and Jan Reimer and Martin Grabowski and Olle Lindvall and Ulf Persson and Peter Hagell",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Section I-II (013230011), Division IV (013230800), Division of Gerontology and Caring Sciences (Closed 2012) (013220200), Restorative Neurology (0131000160), Neurology, Lund (013027000), Caring Sciences (Closed 2012) (016514020)",

year = "2006",

doi = "10.1016/j.parkreldis.2006.04.006",

language = "English",

volume = "12",

pages = "443--452",

journal = "Parkinsonism \& Related Disorders",

issn = "1873-5126",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.

AU - Hjelmgren, Jonas

AU - Ghatnekar, Ola

AU - Reimer, Jan

AU - Grabowski, Martin

AU - Lindvall, Olle

AU - Persson, Ulf

AU - Hagell, Peter

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Section I-II (013230011), Division IV (013230800), Division of Gerontology and Caring Sciences (Closed 2012) (013220200), Restorative Neurology (0131000160), Neurology, Lund (013027000), Caring Sciences (Closed 2012) (016514020)

PY - 2006

Y1 - 2006

N2 - A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved.

AB - A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved.

KW - cell

KW - therapy

KW - cost-effectiveness

KW - Parkinson's disease

KW - outcomes

KW - modeling

UR - https://www.scopus.com/pages/publications/33748764131

U2 - 10.1016/j.parkreldis.2006.04.006

DO - 10.1016/j.parkreldis.2006.04.006

M3 - Article

SN - 1873-5126

VL - 12

SP - 443

EP - 452

JO - Parkinsonism & Related Disorders

JF - Parkinsonism & Related Disorders

IS - 7

ER -

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.

Sammanfattning

Bibliografisk information

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Andra filer och länkar

Fingeravtryck

Citera det här